• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

CHADS-VASc 评分与急性心肌梗死患者行 SVG-PCI 术后血栓负荷的相关性研究。

Association of CHADS-VASc score with thrombus burden in patients with acute myocardial infarction undergoing SVG-PCI.

机构信息

Department of Cardiology, Ankara City Hospital, Ankara, Turkey.

Department of Cardiology, Başakşehir Çam and Sakura City Hospital, Istanbul, Turkey.

出版信息

Herz. 2022 Oct;47(5):456-464. doi: 10.1007/s00059-021-05070-x. Epub 2021 Oct 4.

DOI:10.1007/s00059-021-05070-x
PMID:34608522
Abstract

BACKGROUND

The rate of saphenous vein graft (SVG) occlusion within the first year of bypass graft surgery is 15%. The CHADS-VASc score is used to predict the risk of thromboembolic events in patients with nonvalvular atrial fibrillation. We aimed to evaluate the predictive role of the CHADS-VASc score in the estimation of intracoronary thrombus burden in patients with acute myocardial infarction (AMI) who underwent SVG-PCI.

METHODS

We retrospectively evaluated 221 patients who were admitted with AMI and underwent PCI of SVGs at the Department of Cardiology in the Turkiye Yuksek Ihtisas Education and Research Hospital between 2012 and 2018. The study population was divided into two groups according to their Thrombolysis in Myocardial Infarction (TIMI) thrombus grade: low thrombus burden (LTB; TIMI 0-3) and high thrombus burden (HTB; TIMI 4 and 5).

RESULTS

The study included 221 patients with a mean age of 63.3 ± 6.7 years. The patients with HTB had significantly higher CHADS-VASc scores (p < 0.001) compared with LTB patients. Univariate and multivariate regression analysis demonstrated that both CHADS-VASc score (OR: 1.573, 95% CI: 1.153-2.147, p = 0.004) as a continuous variable and a binary cut-off level of the CHADS-VASc score > 3 (OR: 3.876, 95% CI: 1.705-8.808, p = 0.001) were significantly associated with HTB. The ability of the CHADS-VASc score to predict HTB burden was evaluated by receiver-operating characteristics analysis curve analysis. The optimum cut-off value of the CHADS-VASc score for predicting HTB was 3 (with a sensitivity of 67.9% and a specificity of 69.3%) according to the Youden index.

CONCLUSION

The CHADS-VASc score can be used as an easy practical tool to predict HTB in AMI patients undergoing SVG-PCI.

摘要

背景

旁路移植术后第一年,隐静脉移植物(SVG)闭塞率为 15%。CHADS-VASc 评分用于预测非瓣膜性心房颤动患者血栓栓塞事件的风险。我们旨在评估 CHADS-VASc 评分在预测接受 SVG-PCI 的急性心肌梗死(AMI)患者冠状动脉内血栓负荷中的预测作用。

方法

我们回顾性评估了 2012 年至 2018 年期间在土耳其高等专科教育和研究医院心脏病科因 AMI 接受 SVG-PCI 的 221 例患者。根据他们的血栓溶解在心肌梗死(TIMI)血栓分级,将研究人群分为两组:低血栓负荷(LTB;TIMI 0-3)和高血栓负荷(HTB;TIMI 4 和 5)。

结果

研究纳入了 221 例平均年龄为 63.3±6.7 岁的患者。与 LTB 患者相比,HTB 患者的 CHADS-VASc 评分明显更高(p<0.001)。单因素和多因素回归分析表明,CHADS-VASc 评分(OR:1.573,95%CI:1.153-2.147,p=0.004)作为连续变量和 CHADS-VASc 评分的二分类截断值>3(OR:3.876,95%CI:1.705-8.808,p=0.001)均与 HTB 显著相关。通过受试者工作特征分析曲线分析评估 CHADS-VASc 评分预测 HTB 负荷的能力。根据 Youden 指数,CHADS-VASc 评分预测 HTB 的最佳截断值为 3(灵敏度为 67.9%,特异性为 69.3%)。

结论

CHADS-VASc 评分可作为一种简单实用的工具,用于预测接受 SVG-PCI 的 AMI 患者的 HTB。

相似文献

1
Association of CHADS-VASc score with thrombus burden in patients with acute myocardial infarction undergoing SVG-PCI.CHADS-VASc 评分与急性心肌梗死患者行 SVG-PCI 术后血栓负荷的相关性研究。
Herz. 2022 Oct;47(5):456-464. doi: 10.1007/s00059-021-05070-x. Epub 2021 Oct 4.
2
Predictive accuracy of CHADS-VASc score in determining the high thrombus burden in patients with non-ST-elevation myocardial infarction.CHADS-VASc 评分预测非 ST 段抬高型心肌梗死患者血栓高负荷的准确性。
Acta Cardiol. 2021 Apr;76(2):140-146. doi: 10.1080/00015385.2019.1707934. Epub 2020 Jan 3.
3
Combining clinical predictors to better predict for the no-reflow phenomenon.结合临床预测因子以更好地预测无复流现象。
Eur Rev Med Pharmacol Sci. 2018 Aug;22(15):4987-4994. doi: 10.26355/eurrev_201808_15639.
4
CHA2DS2-VASc Score is a Predictor of No-Reflow in Patients With ST-Segment Elevation Myocardial Infarction Who Underwent Primary Percutaneous Intervention.CHA2DS2-VASc评分是接受直接经皮冠状动脉介入治疗的ST段抬高型心肌梗死患者无复流现象的预测指标。
Angiology. 2016 Oct;67(9):840-5. doi: 10.1177/0003319715622844. Epub 2015 Dec 17.
5
Prognostic value of GRACE and CHA2DS2-VASc score among patients with atrial fibrillation undergoing percutaneous coronary intervention.GRACE和CHA2DS2-VASc评分在接受经皮冠状动脉介入治疗的房颤患者中的预后价值。
Ann Med. 2021 Dec;53(1):2215-2224. doi: 10.1080/07853890.2021.2004321.
6
Usefulness of the CHADS-VASc Score to Predict Adverse Outcomes in Acute Coronary Syndrome Patients Without Atrial Fibrillation Undergoing Percutaneous Coronary Intervention.CHADS-VASc 评分在经皮冠状动脉介入治疗的无房颤急性冠状动脉综合征患者中预测不良结局的价值。
Am J Cardiol. 2019 Aug 15;124(4):476-484. doi: 10.1016/j.amjcard.2019.05.036. Epub 2019 May 29.
7
Prognostic value of CHADS2 and CHA2DS2-VASc scores for post-discharge outcomes in patients with acute coronary syndrome undergoing percutaneous coronary intervention.CHADS2和CHA2DS2-VASc评分对接受经皮冠状动脉介入治疗的急性冠状动脉综合征患者出院后结局的预后价值。
Medicine (Baltimore). 2020 Jul 24;99(30):e21321. doi: 10.1097/MD.0000000000021321.
8
Predictive value of systemic immune-inflammatory index combined with CHA2DS2-VASC score for contrast-induced acute kidney injury in patients with acute coronary syndrome undergoing percutaneous coronary intervention.全身免疫炎症指数联合 CHA2DS2-VASC 评分对行经皮冠状动脉介入治疗的急性冠状动脉综合征患者对比剂诱导急性肾损伤的预测价值。
Int Urol Nephrol. 2023 Nov;55(11):2897-2903. doi: 10.1007/s11255-023-03571-8. Epub 2023 Mar 31.
9
CHA2DS2-VASc Score as an Independent Predictor of Suboptimal Reperfusion and Short-Term Mortality after Primary PCI in Patients with Acute ST Segment Elevation Myocardial Infarction.CHA2DS2-VASc评分作为急性ST段抬高型心肌梗死患者直接经皮冠状动脉介入治疗后再灌注不佳和短期死亡率的独立预测因素
Medicina (Kaunas). 2019 Feb 1;55(2):35. doi: 10.3390/medicina55020035.
10
New CHADS-VASc-HSF score predicts the no-reflow phenomenon after primary percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction.新型 CHADS-VASc-HSF 评分预测 ST 段抬高型心肌梗死患者行直接经皮冠状动脉介入治疗后无复流现象。
BMC Cardiovasc Disord. 2020 Jul 25;20(1):346. doi: 10.1186/s12872-020-01623-w.

引用本文的文献

1
Percutaneous Coronary Intervention Induced-No-reflow in Saphenous Vein Grafts.经皮冠状动脉介入治疗所致大隐静脉桥无复流现象
Arq Bras Cardiol. 2024 Sep 23;121(8):e20240317. doi: 10.36660/abc.20240317. eCollection 2024.
2
Factors Influencing the Risk of No-Reflow Development.影响无复流发生风险的因素
Anatol J Cardiol. 2024 Mar 6;28(5):255-6. doi: 10.14744/AnatolJCardiol.2024.4224.
3
The Predictive Value of the CHA2DS2-VASc Score for In-Stent Restenosis Among Patients with Drug-Eluting Stents Implantation.CHA2DS2-VASc评分对药物洗脱支架植入患者支架内再狭窄的预测价值

本文引用的文献

1
CHA2DS2-VASc score as a predictor of no-reflow phenomenon after saphenous vein graft percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes.CHA2DS2-VASc评分作为非ST段抬高型急性冠状动脉综合征患者隐静脉移植血管经皮冠状动脉介入治疗后无复流现象的预测指标。
Kardiol Pol. 2020 Nov 25;78(11):1129-1136. doi: 10.33963/KP.15603. Epub 2020 Sep 21.
2
Predictive accuracy of CHADS-VASc score in determining the high thrombus burden in patients with non-ST-elevation myocardial infarction.CHADS-VASc 评分预测非 ST 段抬高型心肌梗死患者血栓高负荷的准确性。
Acta Cardiol. 2021 Apr;76(2):140-146. doi: 10.1080/00015385.2019.1707934. Epub 2020 Jan 3.
3
Int J Gen Med. 2023 Jan 5;16:69-76. doi: 10.2147/IJGM.S391312. eCollection 2023.
4
A New Score for Determining Thrombus Burden in STEMI Patients: The MAPH Score.一种用于确定 STEMI 患者血栓负荷的新评分:MAPH 评分。
Clin Appl Thromb Hemost. 2022 Jan-Dec;28:10760296211073767. doi: 10.1177/10760296211073767.
Relationship Between C-Reactive Protein to Albumin Ratio and Thrombus Burden in Patients With Acute Coronary Syndrome.
C 反应蛋白与白蛋白比值与急性冠状动脉综合征患者血栓负荷的关系。
Clin Appl Thromb Hemost. 2019 Jan-Dec;25:1076029618824418. doi: 10.1177/1076029618824418.
4
CHA2DS2-VASc Score as an Independent Predictor of Suboptimal Reperfusion and Short-Term Mortality after Primary PCI in Patients with Acute ST Segment Elevation Myocardial Infarction.CHA2DS2-VASc评分作为急性ST段抬高型心肌梗死患者直接经皮冠状动脉介入治疗后再灌注不佳和短期死亡率的独立预测因素
Medicina (Kaunas). 2019 Feb 1;55(2):35. doi: 10.3390/medicina55020035.
5
2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society.2019年美国心脏协会/美国心脏病学会/心律学会对2014年美国心脏协会/美国心脏病学会/心律学会心房颤动患者管理指南的重点更新:美国心脏病学会/美国心脏协会临床实践指南工作组和心律学会的报告
Heart Rhythm. 2019 Aug;16(8):e66-e93. doi: 10.1016/j.hrthm.2019.01.024. Epub 2019 Jan 28.
6
Predictive Value of CHADS-VASc Score for Ischemic Events in Patients Undergoing Percutaneous Coronary Intervention.CHADS-VASc评分对接受经皮冠状动脉介入治疗患者缺血事件的预测价值。
Angiology. 2019 Oct;70(9):878-886. doi: 10.1177/0003319718804661. Epub 2018 Oct 15.
7
2018 ESC/EACTS Guidelines on myocardial revascularization.2018年欧洲心脏病学会/欧洲心胸外科学会心肌血运重建指南。
Eur Heart J. 2019 Jan 7;40(2):87-165. doi: 10.1093/eurheartj/ehy394.
8
Fourth Universal Definition of Myocardial Infarction (2018).心肌梗死的第四次全球定义(2018年)。
J Am Coll Cardiol. 2018 Oct 30;72(18):2231-2264. doi: 10.1016/j.jacc.2018.08.1038. Epub 2018 Aug 25.
9
Combining clinical predictors to better predict for the no-reflow phenomenon.结合临床预测因子以更好地预测无复流现象。
Eur Rev Med Pharmacol Sci. 2018 Aug;22(15):4987-4994. doi: 10.26355/eurrev_201808_15639.
10
CHA2DS2-VASc Score Predict No-Reflow Phenomenon in Primary Percutaneous Coronary Intervention in Primary Percutaneous Coronary Intervention.CHA2DS2-VASc评分可预测直接经皮冠状动脉介入治疗中的无复流现象。
J Cardiovasc Thorac Res. 2018;10(1):46-52. doi: 10.15171/jcvtr.2018.08. Epub 2018 Mar 18.